Multiple Myeloma | Norton Healthcare

Indication: Multiple Myeloma

An Open-Label, Multicenter, Non-Randomized Phase 2 Study of PF-06863135 Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One ANTI-CD38 Antibody (MM 20-84)

Sub-indication: Hematological Malignancies

Drug Study

Principal Investigator: Don Stevens, M.D.
Norton Cancer Institute

Sponsor: Pfizer

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.